You are here

FTC

FTC says patent battle over Parkinson's drug could have 'significant implications' for patients

FTC says patent battle over Parkinson's drug could have 'significant implications' for patients

Endpoints

Parkinson's Disease

Supernus Pharmaceuticals

Flag link:

In Pfizer-Seagen review, FTC has chance to set new pharma precedent

In Pfizer-Seagen review, FTC has chance to set new pharma precedent

BioPharma Dive

anticompetitive practices

Flag link:

US deal watchdog's bark could be worse than its bite

US deal watchdog's bark could be worse than its bite

EP Vantage

Flag link:

FTC's Non-Compete Law Could Propel Rise in Trade Secrets Lawsuits

FTC's Non-Compete Law Could Propel Rise in Trade Secrets Lawsuits

BioSpace

Flag link:

Warren keeps pressure on pharma, this time targeting Amgen and Indivior buyouts

Warren keeps pressure on pharma, this time targeting Amgen and Indivior buyouts

Fierce Pharma

Elizabeth Warren

Horizon Therapeutics

Opiant Pharmaceuticals

Flag link:

Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban

Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban

Fierce Pharma

Flag link:

Pharma’s digital marketing in crosshairs, as FTC’s plan to curb ‘commercial surveillance’ gains steam

Pharma’s digital marketing in crosshairs, as FTC’s plan to curb ‘commercial surveillance’ gains steam

Medical Marketing and Media

pharma marketing

digital marketing

surveillance marketing

Flag link:

In Jazz case, FTC urges court to delist patent on blockbuster Xyrem

In Jazz case, FTC urges court to delist patent on blockbuster Xyrem

Fierce Pharma

Flag link:

FTC Amicus Brief Challenges Abuse of FDA “Orange Book” Listing Procedures to Block Drug Competition

FTC Amicus Brief Challenges Abuse of FDA “Orange Book” Listing Procedures to Block Drug Competition

FTC

Jazz Pharmaceuticals

Flag link:

EU swats down Illumina's $8B Grail acquisition days after FTC lost antitrust case

EU swats down Illumina's $8B Grail acquisition days after FTC lost antitrust case

Endpoints

Flag link:

Illumina defeats F.T.C. in major antitrust case

Illumina defeats F.T.C. in major antitrust case

NY Times, NY

Flag link:

FTC Unanimously Agrees to Keep Close Eye on PBMs, Higher Drug Costs

FTC Unanimously Agrees to Keep Close Eye on PBMs, Higher Drug Costs

BioSpace

Flag link:

Pharma under the microscope as FTC considers new ways to review acquisitions

Pharma under the microscope as FTC considers new ways to review acquisitions

BioPharma Dive

Flag link:

FTC targets insulin, threatening to go after PBM-pharma deals that steer into 'commercial bribery'

FTC targets insulin, threatening to go after PBM-pharma deals that steer into 'commercial bribery'

Endpoints

Flag link:

Did J&J and BMS conspire on blood thinner price hikes? Congressional leaders want DOJ, FTC to look into it: report

Did J&J and BMS conspire on blood thinner price hikes? Congressional leaders want DOJ, FTC to look into it: report

Fierce Pharma

Bristol Myers Squibb

Flag link:

FTC launches probe into pharmacy benefit management sector

FTC launches probe into pharmacy benefit management sector

Pharmaforum

Flag link:

Pile-on over PBMs continues with FTC comments and a new bipartisan Senate bill

Pile-on over PBMs continues with FTC comments and a new bipartisan Senate bill

Endpoints

Flag link:

Medtronic Hits an FTC Roadblock in Intersect ENT Deal

Medtronic Hits an FTC Roadblock in Intersect ENT Deal

Medical Devices and Diagnostics Industry

Flag link:

FTC deadlocks on vote to launch study into PBM practices

FTC deadlocks on vote to launch study into PBM practices

BioPharma Dive

Flag link:

FTC plots a look into the competitive impact of PBMs on drug prices, pharmacies

FTC plots a look into the competitive impact of PBMs on drug prices, pharmacies

Endpoints

Flag link:

Pages